Product apis-angiogenesis

Home > products > apis> angiogenesis

Catalog	name	Description	price
R-C-2190	Nilotinib (AMN-107) CAS: 641571-10-0	Nilotinib（AMN107)is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.Nilotinib is a selective Bcr-Abl kinase inhibitor that is 10-30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells.	price>
R-C-2192	Degrasyn (WP1130) CAS:856243-80-6	WP1130(Degrasyn)is a novel selective small molecular deubiquitinase inhibitor and a Bcr/Abl destruction pathway activator that specifically and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression in chronic myelogenous leukemia(CML)cells.	price>
R-C-2193	KW-2449 CAS:1000669-72-6	KW-2449 is a multi-targeted kinase inhibitor of FLT3,ABL,ABLT315I and Aurora kinase with IC50s of 6.6,14,4 and 48nM.respectively.	price>
R-C-2196	Rebastinib (DCC-2036) CAS:1020172-07-9	Rebastinib(DCC-2036,)is an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity.Multitargeted tyrosine kinase inhibitor DCC-2036 binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation;in addition,this agent binds to and inhibits Src family kinases LYN,HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2.	price>
R-C-2197	Dasatinib hydrochloride CAS:854001-07-3	Dasatinib(BMS-354825)hydrochloride is a highly potent,ATP competitive,orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity.The Kis are 16 pM and 30 pM for Src and Bcr-Abl,respectively.Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0nM and 0.5nM, respectively.Dasatinib hydrochloride also induces apoptosis and autophagy.	price>
R-C-2198	PD173955 CAS:260415-63-2	PD-173955 is a src tyrosine kinase inhibitor.PD173955 inhibited Bcr-Abl-dependent cell growth.PD173955 has an IC(50)of 1-2 nM in kinase inhibition assays of Bcr-Abl,and in cellular growth assays it inhibits Bcr-Abl-dependent substrate tyrosine phosphorylation.PD173955 inhibited kit ligand-dependent c-kit autophosphorylation(IC(50)=approximately 25nM)and kit ligand-dependent proliferation of M07e cells(IC(50)=40nM)but had a lesser effect on interleukin 3-dependent(IC(50)=250nM)or granulocyte macrophage colony-stimulating factor (IC(50)=1 microM)-dependent cell growth.	price>
R-C-2199	Asciminib (ABL001) CAS:1492952-76-7	Asciminib（ABL001）is a potent allosteric inhibitor of BCR-ABL.ABL001 prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia.Cell proliferation studies demonstrate that ABL001 selectively inhibited the growth of CML and Ph+ ALL cells with potencies ranging from 1-10nM range.	price>
R-C-2200	Berbamine CAS:478-61-5	Berbamine(BA),a traditional Chinese medicines extracted from Berberis amurensis (xiaoboan),is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB,Berbamine(BA)induces apoptosis in human myeloma cells and inhibits the growth of cancer cells by targeting Ca²⁺/calmodulin-dependent protein kinase II (CaMKII).	price>
R-C-2201	GMB-475 CAS:2490599-18-1	GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC,overcoming BCR-ABL1-dependent drug resistance.GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau(VHL),resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.	price>
R-C-2204	Taxifolin (Dihydroquercetin) CAS:480-18-2	Taxifolin((+)-Dihydroquercetin)exhibits important anti-tyrosinase activity.Taxifolin exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3μM.Taxifolin is an important natural compound with antifibrotic activity.Taxifolin is a free radical scavenger with antioxidant capacity.	price>

...